Digene Corporation
This article was originally published in The Gray Sheet
Executive Summary
Gains FDA market go-ahead for its Hybrid Capture II Gonorrhea test for the detection of neisseria gonorrhea DNA in cervical specimens following recent clearance of the firm's Hybrid Capture II CT-ID Chlamydia test. A herpes test is also in development